Share：
Share this content in WeChat
X
[Chinese][PDF]6422
• Review •
Research progress of different MRI techniques in young women breast tumors
NING Ning  LIANG Hongbing  WU Qi  WANG Zhuo  ZHANG Lina 

Cite this article as: NING N, LIANG H B, WU Q, et al. Research progress of different MRI techniques in young women breast tumors[J]. Chin J Magn Reson Imaging, 2023, 14(2): 186-190. DOI:10.12015/issn.1674-8034.2023.02.033.


[Abstract] Breast cancer is the most common malignant tumor in women worldwide and is generally common in middle-aged and older age groups, but in recent years, with changes in living environment and dietary structure, the incidence of breast cancer is becoming more and more youthful. The application of magnetic resonance examination in breast diseases is becoming more and more widespread, and the accuracy of diagnosis of benign and malignant breast lesions has been greatly improved, especially for young women with denser breast tissue. This article reviews the research progress of different magnetic resonance imaging techniques in young women breast tumors, in order to strengthen imaging doctors' understanding of young female breast tumors, especially young breast cancer. It is helpful to pay more attention to early diagnosis and early treatment of breast diseases in young women, so as to improve their quality of life and increase their happiness index.
[Keywords] breast cancer；young women；dynamic contrast enhanced magnetic resonance imaging；diffusion weighted imaging；diffusion tensor imaging；magnetic resonance imaging；functional magnetic resonance imaging；radiomics

NING Ning   LIANG Hongbing   WU Qi   WANG Zhuo   ZHANG Lina*  

Department of Radiology, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, China

*Correspondence to: Zhang LN, E-mail: zln201045@163.com

Conflicts of interest   None.

ACKNOWLEDGMENTS General Project of Teaching Reform Research of Dalian Medical University in 2021 (No. DYLX21036).
Received  2022-08-04
Accepted  2023-01-12
DOI: 10.12015/issn.1674-8034.2023.02.033
Cite this article as: NING N, LIANG H B, WU Q, et al. Research progress of different MRI techniques in young women breast tumors[J]. Chin J Magn Reson Imaging, 2023, 14(2): 186-190. DOI:10.12015/issn.1674-8034.2023.02.033.

[1]
SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2016[J]. CA A Cancer J Clin, 2016, 66(1): 7-30. DOI: 10.3322/caac.21332.
[2]
China Guideline Committee of Clinical Practice and Fertility Preservation for Breast Cancer in Young Women. Chinese consensus guidelines for breast cancer in young women: clinical practice and fertility preservation[J]. Chin J Oncol, 2019, 41(7): 486-495. DOI: 10.3760/cma.j.issn.0253?3766.2019.07.002.
[3]
ROSSI L, MAZZARA C, PAGANI O. Diagnosis and Treatment of Breast Cancer in Young Women[J/OL]. Curr Treat Options Oncol, 2019, 20(12): 86 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/31776799/. DOI: 10.1007/s11864-019-0685-7.
[4]
BILLENA C, WILGUCKI M, FLYNN J, et al. 10-year breast cancer outcomes in women ≤35 years of age[J]. Int J Radiat Oncol Biol Phys, 2021, 109(4): 1007-1018. DOI: 10.1016/j.ijrobp.2020.10.022.
[5]
SHOEMAKER M L, WHITE M C, WU M X, et al. Differences in breast cancer incidence among young women aged 20-49 years by stage and tumor characteristics, age, race, and ethnicity, 2004-2013[J]. Breast Cancer Res Treat, 2018, 169(3): 595-606. DOI: 10.1007/s10549-018-4699-9.
[6]
NARAYAN A K, VISVANATHAN K, HARVEY S C. Comparative effectiveness of breast MRI and mammography in screening young women with elevated risk of developing breast cancer: a retrospective cohort study[J]. Breast Cancer Res Treat, 2016, 158(3): 583-589. DOI: 10.1007/s10549-016-3912-y.
[7]
PARK A R, CHAE E Y, CHA J H, et al. Preoperative breast MRI in women 35 years of age and younger with breast cancer: benefits in surgical outcomes by using propensity score analysis[J]. Radiology, 2021, 300(1): 39-45. DOI: 10.1148/radiol.2021204124.
[8]
YU Y, TAN Y, XIE C, et al. Development and Validation of a Preoperative Magnetic Resonance Imaging Radiomics-Based Signature to Predict Axillary Lymph Node Metastasis and Disease-Free Survival in Patients With Early-Stage Breast Cancer[J/OL]. JAMA Netw Open, 2020, 3(12): e2028086 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/33289845/. DOI: 10.1001/jamanetworkopen.2020.28086.
[9]
SOPIK V. International variation in breast cancer incidence and mortality in young women[J]. Breast Cancer Res Treat, 2021, 186(2): 497-507. DOI: 10.1007/s10549-020-06003-8.
[10]
ZHANG W, ZHANG B L, HE J J, et al. Clinicopathological characteristics and treatment of young women with breast cancer in China: a nationwide multicenter 10-year retrospective study[J]. Gland Surg, 2021, 10(1): 175-185. DOI: 10.21037/gs-20-574.
[11]
EIRIZ I F, BATISTA M VAZ, CRUZ TOMÁS T, et al. Breast cancer in very young women-a multicenter 10-year experience[J/OL]. ESMO Open, 2021, 6(1): 100029 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/33399090/. DOI: 10.1016/j.esmoop.2020.100029.
[12]
FU J, WU L, FU W, et al. How Young Is Too Young in Breast Cancer?- Young Breast Cancer Is Not a Unique Biological Subtype[J/OL]. Clin Breast Cancer, 2018, 18(1): e25-e39 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/28802528/. DOI: 10.1016/j.clbc.2017.05.015.
[13]
PALUCH-SHIMON S, CARDOSO F, PARTRIDGE A H, et al. ESO-ESMO 4th international consensus guidelines for breast cancer in young women (BCY4)[J]. Ann Oncol, 2020, 31(6): 674-696. DOI: 10.1016/j.annonc.2020.03.284.
[14]
STACHS A, STUBERT J, REIMER T, et al. Benign breast disease in women[J]. Deutsches Ärzteblatt Int, 2019, 116(33-34): 565-574. DOI: 10.3238/arztebl.2019.0565.
[15]
MENG X, YAMANOUCHI K, KUBA S, et al. Giant fibroadenoma of the breast: A rare case in a mature woman[J/OL]. Int J Surg Case Rep, 2019, 63: 36-39 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/31561187/. DOI: 10.1016/j.ijscr.2019.09.015.
[16]
GUTKIN P M, GANJOO K N, LOHMAN M, et al. Angiosarcoma of the breast: management and outcomes[J]. Am J Clin Oncol, 2020, 43(11): 820-825. DOI: 10.1097/COC.0000000000000753.
[17]
TAY T K Y, TAN P H. Papillary neoplasms of the breast—reviewing the spectrum[J]. Mod Pathol, 2021, 34(6): 1044-1061. DOI: 10.1038/s41379-020-00732-3.
[18]
PENG F, LI J, MU S, et al. Epidemiological features of primary breast lymphoma patients and development of a nomogram to predict survival[J/OL]. Breast, 2021, 57: 49-61 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/33774459/. DOI: 10.1016/j.breast.2021.03.006.
[19]
ERIĆ I, PETEK ERIĆ A, KRISTEK J, et al. Breast cancer in young women: pathologic and immunohistochemical features[J]. Acta Clin Croat, 2018, 57(3): 497-502. DOI: 10.20471/acc.2018.57.03.13.
[20]
PUSZTAI L, FOLDI J, DHAWAN A, et al. Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers[J/OL]. Lancet Oncol, 2019, 20(7): e390-e396d [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/31267973/. DOI: 10.1016/s1470-2045(19)30158-5.
[21]
YAP Y S, LU Y S, TAMURA K, et al. Insights into breast cancer in the east vs the west: a review[J]. JAMA Oncol, 2019, 5(10): 1489-1496. DOI: 10.1001/jamaoncol.2019.0620.
[22]
MILLER I, MIN M W, YANG C, et al. Ki67 is a Graded Rather than a Binary Marker of Proliferation versus Quiescence[J]. Cell Rep, 2018, 24(5): 1105-1112.e5. DOI: 10.1016/j.celrep.2018.06.110.
[23]
DAI D, ZHONG Y, WANG Z, et al. The prognostic impact of age in different molecular subtypes of breast cancer: a population-based study[J/OL]. Peer J, 2019, 7: e7252 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/31309004/. DOI: 10.7717/peerj.7252.
[24]
SPRATT D E. Ki-67 remains solely a prognostic biomarker in localized prostate cancer[J]. Int J Radiat Oncol Biol Phys, 2018, 101(3): 513-515. DOI: 10.1016/j.ijrobp.2018.03.008.
[25]
LEE J, KIM S H, KANG B J, et al. Imaging characteristics of young age breast cancer (YABC) focusing on pathologic correlation and disease recurrence[J/OL]. Sci Rep, 2021, 11(1): 20205 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/34642389/. DOI: 10.1038/s41598-021-99600-6.
[26]
MOUHOUB M, MIRY A, HALOUI A, et al. Primary angiosarcoma of the breast: a case report[J/OL]. Pan Afr Med J, 2019, 33: 134 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/31558933/. DOI: 10.11604/pamj.2019.33.134.17414.
[27]
SHARMA S, NWACHUKWU C, WIESELER C, et al. MRI Virtual Biopsy of T2 Hyperintense Breast Lesions[J/OL]. J Clin Imaging Sci, 2021, 11: 18 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/33880243/. DOI: 10.25259/jcis_42_2021.
[28]
HUANG J L, LIN Q, CUI C X, et al. Correlation between imaging features and molecular subtypes of breast cancer in young women (≤30 years old)[J]. Jpn J Radiol, 2020, 38(11): 1062-1074. DOI: 10.1007/s11604-020-01001-8.
[29]
HARADA T L, UEMATSU T, NAKASHIMA K, et al. Evaluation of breast edema findings at T2-weighted breast MRI is useful for diagnosing occult inflammatory breast cancer and can predict prognosis after neoadjuvant chemotherapy[J]. Radiology, 2021, 299(1): 53-62. DOI: 10.1148/radiol.2021202604.
[30]
CHEON H, KIM H J, KIM T H, et al. Invasive breast cancer: prognostic value of peritumoral edema identified at preoperative MR imaging[J]. Radiology, 2018, 287(1): 68-75. DOI: 10.1148/radiol.2017171157.
[31]
ZHANG M, HORVAT J V, BERNARD-DAVILA B, et al. Multiparametric MRI model with dynamic contrast-enhanced and diffusion-weighted imaging enables breast cancer diagnosis with high accuracy[J]. J Magn Reson Imaging, 2019, 49(3): 864-874. DOI: 10.1002/jmri.26285.
[32]
CHENG Q, HUANG J, LIANG J, et al. The Diagnostic Performance of DCE-MRI in Evaluating the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis[J/OL]. Front Oncol, 2020, 10: 93 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/32117747/. DOI: 10.3389/fonc.2020.00093.
[33]
JIANG L, ZHOU Y M, WANG Z, et al. Is there different correlation with prognostic factors between "non-mass" and "mass" type invasive ductal breast cancers?[J]. Eur J Radiol, 2013, 82(9): 1404-1409. DOI: 10.1016/j.ejrad.2013.03.006.
[34]
BITENCOURT A G V, EUGÊNIO D S G, SOUZA J A, et al. Prognostic significance of preoperative MRI findings in young patients with breast cancer[J/OL]. Sci Rep, 2019, 9(1): 3106 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/30816243/. DOI: 10.1038/s41598-019-39629-w.
[35]
WATT G P, SUNG J, MORRIS E A, et al. Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study[J/OL]. Breast Cancer Res, 2020, 22(1): 138 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/33287857/. DOI: 10.1186/s13058-020-01375-7.
[36]
KAMITANI T, YABUUCHI H, KANEMAKI Y, et al. Effects of menstrual cycle on background parenchymal enhancement and detectability of breast cancer on dynamic contrast-enhanced breast MRI: A multicenter study of an Asian population[J/OL]. Eur J Radiol, 2019, 110: 130-135 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/30599849/. DOI: 10.1016/j.ejrad.2018.11.025.
[37]
DONTCHOS B N, RAHBAR H, PARTRIDGE S C, et al. Influence of menstrual cycle timing on screening breast MRI background parenchymal enhancement and diagnostic performance in premenopausal women[J]. J Breast Imaging, 2019, 1(3): 205-211. DOI: 10.1093/jbi/wbz022.
[38]
DURHAN G, AZIZOVA A, ÖNDER Ö, et al. Imaging findings and clinicopathological correlation of breast cancer in women under 40 years old[J]. Eur J Breast Health, 2019, 15(3): 147-152. DOI: 10.5152/ejbh.2019.4606.
[39]
ZHANG Q Q, QIAN W J, YE F, et al. MRI features of different molecular subtypes of breast cancer in young women[J]. J Pract Radiol, 2021, 37(7): 1094-1098. DOI: 10.3969/j.issn.1002-1671.2021.07.012.
[40]
LI Y C, ZHANG L, LIANG W, et al. Differential diagnosis of breast medullary carcinoma and fibroadenoma by MRI[J]. Chin J Magn Reson Imaging, 2020, 11(2): 124-128. DOI: 10.12015/issn.1674-8034.2020.02.010.
[41]
WU W H, JI Q L, LI Z Z, et al. Mammography and MRI manifestations of breast angiosarcoma[J/OL]. BMC Womens Health, 2019, 19(1): 73 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/31182098/. DOI: 10.1186/s12905-019-0769-3.
[42]
BROWN A L, WAHAB R A. MRI of Primary Angiosarcoma of the Breast[J/OL]. Radiology, 2020, 297(1): 31 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/32720871/. DOI: 10.1148/radiol.2020201377.
[43]
MUMIN N A, RAHMAT K, HAMID M T R, et al. Primary breast angiosarcoma: utilisation of pre-surgical magnetic resonance imaging (MRI) for accurate tumour characterization and planning-A case report and literature review[J]. Curr Med Imaging, 2021, 17(4): 552-558. DOI: 10.2174/1573405616666201007161119.
[44]
FAN Q J, TAN H, YANG Q, et al. The research of multi-parameter MRI evaluation of young women with normal breast tissues changes during the menstrual cycle[J]. J Clin Radiol, 2018, 37(8): 1283-1287. DOI: 10.13437/j.cnki.jcr.2018.08.011.
[45]
SPRINGER C S J R. Using 1H2O MR to measure and map sodium pump activity in vivo[J/OL]. J Magn Reson, 2018, 291: 110-126 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/29705043/. DOI: 10.1016/j.jmr.2018.02.018.
[46]
LV X F, HU S P. Correlation of T2WI characteristics with ADC value and ki-67 expression in young women with invasive ductal carcinoma[J]. Comput Tomogr Theory Appl, 2020, 29(1): 49-54. DOI: 10.15953/j.1004-4140.2020.29.01.06.
[47]
YALCIN A, GOKTEPELI M, TAYDAS O, et al. Native T1 mapping of the breast in MRI to differentiate fibroadenomas from benign phyllodes tumors: a preliminary study[J]. MAGMA, 2022, 35(3): 441-447. DOI: 10.1007/s10334-021-00969-2.
[48]
LOI L, GOERKE S, ZIMMERMANN F, et al. Assessing the influence of the menstrual cycle on APT CEST-MRI in the human breast[J/OL]. Magn Reson Imaging, 2022, 91: 24-31 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/35550841/. DOI: 10.1016/j.mri.2022.05.006.
[49]
CONTI A, DUGGENTO A, INDOVINA I, et al. Radiomics in breast cancer classification and prediction[J/OL]. Semin Cancer Biol, 2021, 72: 238-250 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/32371013/. DOI: 10.1016/j.semcancer.2020.04.002.
[50]
LI Q, DORMER J, DARYANI P, et al. Radiomics Analysis of MRI for Predicting Molecular Subtypes of Breast Cancer in Young Women[J/OL]. Proc SPIE Int Soc Opt Eng, 2019, 10950: 1095044 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/32528211/. DOI: 10.1117/12.2512056.
[51]
JIANG N P, ZHONG L, ZHANG C L, et al. Value of conventional MRI texture analysis in the differential diagnosis of Phyllodes tumors and fibroadenomas of the breast[J]. Breast Care (Basel), 2021, 16(3): 283-290. DOI: 10.1159/000508456.
[52]
MAI H, MAO Y, DONG T, et al. The Utility of Texture Analysis Based on Breast Magnetic Resonance Imaging in Differentiating Phyllodes Tumors From Fibroadenomas[J/OL]. Front Oncol, 2019, 9: 1021 [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/31681572/. DOI: 10.3389/fonc.2019.01021.

PREV Application and research progress of magnetic resonance parameter quantitative technique in myocardial involvement diseases
NEXT Research progress in imaging evaluation of liver metastases in colorectal cancer
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn